Tonix Pharmaceuticals Holding Corp. (TNXP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tonix Pharmaceuticals Holding Corp. on March 3, 2026. The report discloses a corporate event regarding the listing status of the Company's common stock on The NASDAQ Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing event and does not contain financial performance data.
Material Changes
- Listing Transfer: The Company received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Capital Market to The Nasdaq Global Select Market.
- Effective Date: The transfer commenced at the open of market on March 3, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The document serves solely to announce the listing upgrade under Regulation FD (Item 7.01) and Other Events (Item 8.01).
Investor Verification Checklist
- Verify the effective trading date of the listing transfer (March 3, 2026).
- Confirm the new listing venue is The Nasdaq Global Select Market.
- Review the attached Press Release (Exhibit 99.01) for additional context not included in the 8-K body.
- Note that this filing does not include updated financial statements or operational metrics.